NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Eloxx Pharmaceuticals, Inc. (ELOX) Stock Analysis

Eloxx Pharmaceuticals, Inc. (ELOX) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

ELOX

$15.00

+$0.81 (+5.71%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ELOX with… →

ELOX Key Statistics

As of Sep 4, 2026
Trading
Open
$14.06
Previous Close
$14.19
Day's Range
14.06–16.48
52-Week Range
8.20–23.40
Volume
38.80K
Valuation
Market Cap
$51.54M
P/E Ratio
4.26
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.85
EPS (ttm)Profit attributable to each share over the last twelve months.
3.52
Financials (FY)
Revenue (FY)
$0.00−100.00%
Net Income (FY)
−$6.00M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
3.44M
Dividend and dates
Avg Volume
59.14K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

ELOX Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$6.00M—
2024$6.36M−$3.14M−49.4%
2023$0.00−$17.05M—
2022$0.00−$36.07M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$6.44M−$6.00M—
2024$6.36M—−$2.47M−$3.14M−49.4%
2023$0.00—−$17.29M−$17.05M—
2022$0.00—−$34.42M−$36.07M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ELOX Valuation vs Biotechnology Median

Median of 656 stocks
MetricELOXBiotechnology medianvs median
P/E4.2612.5766% below
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Eloxx Pharmaceuticals, Inc. (ELOX) at $51.54M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 10 employees.

The most recent close on file for ELOX is $15.00, dated September 4, 2026. That is +$0.81 (+5.71%) against the previous close. Over the past 52 weeks the price has ranged from $8.20 to $23.40. The latest close sits 82.93% above that 52-week low.

Financial Health

In fiscal 2025, Eloxx Pharmaceuticals, Inc. reported revenue of $0.00. That is −100.00% against the prior fiscal year, when revenue was $6.36M. The same year closed with a net loss of $6.00M. The reported profit margin is 0%. Earnings per share on a trailing basis come to 3.52.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 4.26 times earnings. That is 66.11% below the Biotechnology median of 12.57. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.85. The medians here are taken across 656 Biotechnology companies that report the metric.

Growth & Income

The record shows no dividend for ELOX.

2026 is still running; the price is +36.24% year to date.

Peer Comparison

Eloxx Pharmaceuticals, Inc. (ELOX) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Eloxx Pharmaceuticals, Inc. ELOX $51.54M 4.3
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Eloxx Pharmaceuticals, Inc. trades at a P/E of 4.3.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Eloxx Pharmaceuticals, Inc.

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney diseases, including Alport syndrome with nonsense mutations, cystic fibrosis with nonsense mutations, and nephropathic cystinosis with nonsense mutations, as well as in a preclinical stage for the treatment of autosomal dominant polycystic kidney disease with nonsense mutations. It has collaboration with Almirall, S.A. to develop and commercialize ZKN-013, an oral ribosome modulating agent for the treatment of rare skin diseases, such as recessive dystrophic epidermolysis bullosa and junctional epidermolysis bullosa with nonsense mutations. Eloxx Pharmaceuticals, Inc. was incorporated in 1999 and is based in Arlington, Massachusetts.

Visit website →